-$3.32 EPS Expected for SAGE Therapeutics Inc (NASDAQ:SAGE) This Quarter

Brokerages expect SAGE Therapeutics Inc (NASDAQ:SAGE) to announce ($3.32) earnings per share (EPS) for the current fiscal quarter, Zacks reports. Three analysts have provided estimates for SAGE Therapeutics’ earnings, with the lowest EPS estimate coming in at ($3.63) and the highest estimate coming in at ($2.89). SAGE Therapeutics reported earnings of ($0.36) per share in the same quarter last year, which would indicate a negative year-over-year growth rate of 822.2%. The business is expected to issue its next earnings results on Tuesday, August 6th.

On average, analysts expect that SAGE Therapeutics will report full year earnings of ($13.19) per share for the current financial year, with EPS estimates ranging from ($14.54) to ($11.34). For the next year, analysts anticipate that the firm will post earnings of ($11.76) per share, with EPS estimates ranging from ($16.21) to ($8.85). Zacks Investment Research’s EPS calculations are an average based on a survey of analysts that follow SAGE Therapeutics.

SAGE Therapeutics (NASDAQ:SAGE) last announced its earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($3.37) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($3.17) by ($0.20). The business had revenue of $0.47 million during the quarter. During the same period last year, the business posted ($1.68) EPS.

A number of equities analysts have issued reports on the company. Jefferies Financial Group assumed coverage on SAGE Therapeutics in a research report on Thursday, April 25th. They issued a “buy” rating and a $195.00 target price on the stock. ValuEngine lowered SAGE Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Thursday, April 18th. Canaccord Genuity set a $220.00 price objective on SAGE Therapeutics and gave the stock a “buy” rating in a research note on Monday, April 8th. Oppenheimer set a $170.00 price target on SAGE Therapeutics and gave the stock a “buy” rating in a research note on Sunday, May 5th. Finally, Wedbush started coverage on SAGE Therapeutics in a research note on Wednesday, May 22nd. They set an “outperform” rating and a $207.00 target price for the company. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and fifteen have assigned a buy rating to the company. The stock has an average rating of “Buy” and an average price target of $202.15.

Shares of SAGE opened at $169.60 on Friday. SAGE Therapeutics has a 52-week low of $79.88 and a 52-week high of $178.16. The company has a market capitalization of $8.99 billion, a price-to-earnings ratio of -20.99 and a beta of 2.66. The company has a current ratio of 20.06, a quick ratio of 20.06 and a debt-to-equity ratio of 0.03.

In related news, Director Steven M. Paul sold 60,421 shares of SAGE Therapeutics stock in a transaction that occurred on Wednesday, March 20th. The shares were sold at an average price of $161.28, for a total value of $9,744,698.88. Following the sale, the director now owns 272,777 shares of the company’s stock, valued at approximately $43,993,474.56. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Steven M. Paul sold 3,775 shares of SAGE Therapeutics stock in a transaction that occurred on Monday, March 18th. The stock was sold at an average price of $161.05, for a total transaction of $607,963.75. Following the completion of the sale, the director now directly owns 272,777 shares in the company, valued at approximately $43,930,735.85. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 291,121 shares of company stock valued at $49,791,439. 4.60% of the stock is currently owned by company insiders.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. M&R Capital Management Inc. purchased a new position in SAGE Therapeutics during the fourth quarter worth about $28,000. Benjamin F. Edwards & Company Inc. purchased a new position in shares of SAGE Therapeutics during the fourth quarter worth approximately $29,000. Daiwa Securities Group Inc. grew its position in shares of SAGE Therapeutics by 34.8% during the fourth quarter. Daiwa Securities Group Inc. now owns 310 shares of the biopharmaceutical company’s stock worth $30,000 after acquiring an additional 80 shares during the last quarter. Icon Wealth Partners LLC purchased a new position in shares of SAGE Therapeutics during the first quarter worth approximately $31,000. Finally, Mckinley Capital Management LLC Delaware grew its position in shares of SAGE Therapeutics by 53.3% during the first quarter. Mckinley Capital Management LLC Delaware now owns 282 shares of the biopharmaceutical company’s stock worth $45,000 after acquiring an additional 98 shares during the last quarter.

About SAGE Therapeutics

Sage Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system (CNS) disorders. Its lead product candidate is ZULRESSO, a proprietary intravenous formulation of brexanolone that has completed Phase III clinical trials for the treatment of postpartum depression (PPD).

Further Reading: How is the LIBOR rate calculated?

Get a free copy of the Zacks research report on SAGE Therapeutics (SAGE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for SAGE Therapeutics (NASDAQ:SAGE)

Receive News & Ratings for SAGE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAGE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.